Zoetis Inc. (NYSE:ZTS) Receives Average Rating of “Hold” from Analysts

Zoetis Inc. (NYSE:ZTS) has been assigned a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $152.9091.

Several research firms have recently commented on ZTS. KeyCorp began coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating for the company. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. UBS Group set a $136.00 price target on Zoetis in a report on Thursday, January 29th. Barclays assumed coverage on Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th.

Hedge Funds Weigh In On Zoetis

Several large investors have recently added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC raised its position in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Global Wealth Strategies & Associates bought a new position in Zoetis in the 4th quarter worth $25,000. Prosperity Bancshares Inc bought a new position in Zoetis in the 4th quarter worth $25,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis in the 4th quarter worth $30,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis in the 3rd quarter worth $31,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $115.62 on Friday. The firm’s 50 day moving average price is $125.34 and its 200-day moving average price is $131.75. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The stock has a market capitalization of $48.81 billion, a PE ratio of 19.21, a price-to-earnings-growth ratio of 1.76 and a beta of 0.95. Zoetis has a twelve month low of $114.47 and a twelve month high of $172.23.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the prior year, the company earned $1.40 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts expect that Zoetis will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.